LEXINGTON, Mass. and AMSTERDAM, Sept. 30, 2021 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences:
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with severe genetic diseases of the central nervous system (CNS) and liver, including clinical programs in hemophilia B and Huntington’s disease and preclinical candidates in Fabry disease, spinocerebellar ataxia Type 3, temporal lobe epilepsy, Alzheimer’s, Parkinson’s, and ALS. www.uniQure.com
uniQure Contacts: | ||||
FOR INVESTORS: | FOR MEDIA: | |||
Maria E. Cantor | Chiara Russo | Tom Malone | ||
Direct: 339-970-7536 | Direct: 617-306-9137 | Direct: 339-970-7558 | ||
m.cantor@uniQure.com | c.russo@uniQure.com | t.malone@uniQure.com |
Evidence-informed course equips non-professionals to respond to mental health crises with practical, scalable skills Project…
-- Femasys continues to expand access and market share for its first-line infertility treatment option,…
All three patients treated with FT819 following fludarabine-free conditioning regimen for severe lupus nephritis achieve…
SARASOTA, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or…
Vanessa Tolosa joins as Senior Vice President of Research and Development; Vivek Pinto as Director…
BEIJING, June 11, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. ("Shineco" or the "Company"; NASDAQ: SISI),…